Bridging Clinical Outcomes and Cost-Effectiveness: The Role of Real-World Data in Cystic Fibrosis Therapy.
作者信息
Štimac Ida, Faour Andrea Katrin, Gkrinia Elvira Meni Maria, Belančić Andrej
机构信息
Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
Independent Researcher, Vancouver, British Columbia, Canada.
出版信息
Pharmacol Res Perspect. 2025 Aug;13(4):e70138. doi: 10.1002/prp2.70138.
Abstract
摘要
相似文献
1
Bridging Clinical Outcomes and Cost-Effectiveness: The Role of Real-World Data in Cystic Fibrosis Therapy.连接临床结果与成本效益：真实世界数据在囊性纤维化治疗中的作用。
Pharmacol Res Perspect. 2025 Aug;13(4):e70138. doi: 10.1002/prp2.70138.
2
Exploring the role of microbiome in cystic fibrosis clinical outcomes through a mediation analysis.通过中介分析探索微生物群落在囊性纤维化临床结局中的作用。
mSystems. 2025 Jun 17;10(6):e0019625. doi: 10.1128/msystems.00196-25. Epub 2025 May 28.
3
Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy.囊性纤维化跨膜传导调节因子调节剂对孕期及产后母体结局的影响。
Chest. 2025 Feb;167(2):348-361. doi: 10.1016/j.chest.2024.09.019. Epub 2024 Sep 27.
4
Real-World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation.在开始使用依列卡福妥/替扎卡福妥/依伐卡福妥后，囊性纤维化患儿肺清除指数和通气分布效率的真实世界改善情况。
Pediatr Pulmonol. 2025 Jun;60(6):e71166. doi: 10.1002/ppul.71166.
5
A real-world retrospective cohort study: the clinical outcomes and characteristics of platinum-resistant recurrent ovarian cancer.一项真实世界回顾性队列研究：铂耐药复发性卵巢癌的临床结局与特征
Transl Cancer Res. 2025 May 30;14(5):3161-3174. doi: 10.21037/tcr-2025-641. Epub 2025 May 27.
6
Diseases Common in Persons With Cystic Fibrosis Among CFTR Heterozygotes.CFTR杂合子中囊性纤维化患者常见的疾病。
JAMA Intern Med. 2025 Jun 16. doi: 10.1001/jamainternmed.2025.1853.
7
Impact of elexacaftor/tezacaftor/ivacaftor on the small airways in cystic fibrosis.依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化患者小气道的影响。
J Bras Pneumol. 2025 Jun 13;51(2):e20240406. doi: 10.36416/1806-3756/e20240406. eCollection 2025.
8
Impact of availability of a highly effective cystic fibrosis treatment (elexacaftor/tezacaftor/ivacaftor) on lung transplant waitlist and lung transplantation trends in the US.一种高效囊性纤维化治疗药物（依列卡福/替扎卡福/依伐卡福）的可及性对美国肺移植等待名单及肺移植趋势的影响
Respir Med. 2025 Aug-Sep;245:108171. doi: 10.1016/j.rmed.2025.108171. Epub 2025 May 21.
9
Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).哌柏西利联合内分泌治疗用于日本HR+/HER2-晚期乳腺癌患者一线或二线治疗的总生存期：一项多中心观察性研究（P-BRIDGE研究）
Breast Cancer. 2025 Apr 5. doi: 10.1007/s12282-025-01689-4.
10
Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States.在美国真实世界环境中接受治疗的转移性三阴性乳腺癌患者中，戈沙妥珠单抗的疗效及中性粒细胞减少的管理。
ESMO Open. 2025 Jun;10(6):105308. doi: 10.1016/j.esmoop.2025.105308. Epub 2025 Jun 5.
本文引用的文献
1
Improved Clinical Outcomes With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease: Real-World Evidence From an Italian Single-Center Study.依列卡福妥/替扎卡福妥/依伐卡托治疗囊性纤维化和晚期肺部疾病患者的临床结局改善：来自意大利单中心研究的真实世界证据
Pharmacol Res Perspect. 2025 Apr;13(2):e70083. doi: 10.1002/prp2.70083.
2
Navigating challenges and opportunities in orphan medicines: A spotlight commentary on rare diseases.应对孤儿药领域的挑战与机遇：关于罕见病的聚焦评论
Br J Clin Pharmacol. 2025 Apr;91(4):1084-1087. doi: 10.1002/bcp.70013. Epub 2025 Feb 16.
3
Could choosing risdiplam instead of nusinersen in the treatment of type 1 spinal muscular atrophy be a huge cost-minimization opportunity?在1型脊髓性肌萎缩症的治疗中选择利司扑兰而非诺西那生钠会是一个巨大的成本最小化机会吗？
Croat Med J. 2024 Oct 31;65(5):454-456. doi: 10.3325/cmj.2024.65.454.
4
A systematic review of economic evaluations of orphan medicines for the management of spinal muscular atrophy.对用于治疗脊髓性肌萎缩症的孤儿药的经济学评估的系统评价。
Br J Clin Pharmacol. 2025 Jan;91(1):95-116. doi: 10.1111/bcp.16267. Epub 2024 Oct 8.
5
Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations.伊伐卡托对囊性纤维化患者和特定伊伐卡托反应性突变体的真实世界影响。
BMJ Open Respir Res. 2024 Jul 29;11(1):e002033. doi: 10.1136/bmjresp-2023-002033.
6
Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Real-World Evidence Highlights Need for Worldwide Access.囊性纤维化跨膜传导调节因子调节剂：真实世界证据凸显全球可及性需求。
Ann Am Thorac Soc. 2024 Jul;21(7):1003-1004. doi: 10.1513/AnnalsATS.202404-439ED.
7
Past, present and future of drug safety: Editorial.药物安全的过去、现在与未来：社论
Br J Clin Pharmacol. 2024 Aug;90(8):1760-1762. doi: 10.1111/bcp.16140. Epub 2024 Jun 16.
8
Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.依列卡福妥-替扎卡福妥-依伐卡托治疗囊性纤维化的疗效与安全性：一项系统评价
Children (Basel). 2023 Mar 15;10(3):554. doi: 10.3390/children10030554.
9
Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience.欧洲和美国的医疗保健系统：有条件准入协议的经验
Healthcare (Basel). 2023 Feb 3;11(3):447. doi: 10.3390/healthcare11030447.
10
The politics of universal health coverage.全民健康覆盖的政治。
Lancet. 2022 May 28;399(10340):2066-2074. doi: 10.1016/S0140-6736(22)00585-2. Epub 2022 May 17.
Zotero 插件